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Abstract
Background
The soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hook-
worms, infect 1.5 billion people worldwide and cause an estimated burden of 3.3 million dis-
ability-adjusted life years (DALYs). Current control strategies focus on morbidity reduction
through preventive chemotherapy (PC) but the most commonly used recommended drugs
(albendazole and mebendazole) are particularly inefficacious against T. trichiura. This,
together with the threat of emerging drug resistance, calls for new control strategies, includ-
ing co-administration with other anthelminthics. Ivermectin plus albendazole is widely used
against lymphatic filariasis, but its efficacy and safety against STH infections has not yet
been fully understood.
Methods and findings
We conducted a systematic literature review and meta-analysis on the efficacy and safety of
ivermectin-albendazole co-administration in five different databases (i.e. PubMed, ISI Web
of Science, ScienceDirect, CENTRAL and clinicaltrials.gov) from 1960 to January 2018.
Four studies reporting efficacy of ivermectin-albendazole against STH infections and five
studies on its safety met the selection criteria and were included for quantitative analysis.
Ivermectin-albendazole was significantly associated with lower risk (risk ratio (RR) = 0.44,
95% confidence interval (CI) = 0.31–0.62) for T. trichiura infection after treatment compared
to albendazole alone. The co-administration revealed no or only a marginal benefit on cure
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and egg reduction rates over albendazole alone for A. lumbricoides and hookworm infec-
tions. Adverse events (AEs) occurring after ivermectin-albendazole co-administration were
mostly mild and transient. Overall, the number of individuals reporting any AE was not differ-
ent (RR = 1.09, 95% CI = 0.87–1.36) in co-treated and albendazole-treated patients. How-
ever, although not statistically significant, sub-group analysis showed a tendency for slightly
more AEs in patients with filariasis treated with ivermectin-albendazole compared to those
treated with albendazole alone (RR = 1.29, 95% CI = 0.81–2.05).
Conclusions
Our findings suggest a good tolerability and higher efficacy of ivermectin-albendazole
against T. trichiura compared to the current standard single-dose albendazole treatment,
which supports the use of this co-administration in PC programs. Large-scale definitive ran-
domized controlled trials are required to confirm our results.
Author summary
Millions of people worldwide are infected with intestinal worms known as soil-transmit-
ted helminths (STHs). These include Ascaris lumbricoides, hookworm (Ancylostoma duo-
denale and Necator americanus) and Trichuris trichiura. Globally, the current main
strategy to control these parasites is the periodical distribution of treatment to populations
which are at particular risk of infection. However, the two drugs exclusively used in these
mass treatment campaigns (albendazole and mebendazole) do not perform well against
some of the STH species. Adding another drug, such as ivermectin, to albendazole holds
promise for improved performance. This combination is already being widely used for
the treatment of lymphatic filariasis. However, policy makers need evidence that this co-
administration is efficacious and safe when taken together for STH infections. To fill this
knowledge gap, we systematically reviewed the scientific literature for studies on the effi-
cacy and safety of the co-administration of ivermectin and albendazole. We identified
four studies reporting on the efficacy of the co-treated and five studies assessing their tol-
erability. Our results suggest that the co-administration performs significantly better than
albendazole alone against T. trichiura–the STH species which is most difficult to treat–
and is generally well-tolerated. Yet, we conclude that definitive evidence to support the
use of ivermectin together with albendazole for STH will require more high-quality
studies.
Introduction
Soil-transmitted helminths (STHs) collectively cause the most widespread neglected tropical
disease (NTD): nearly 1.5 billion people are infected with Ascaris lumbricoides, Trichuris tri-
chiura, and/or hookworm (i.e. Necator americanus and Ancylostoma duodenale) in over 100
endemic countries [1, 2] and 3.3 million disability-adjusted life years (DALYs) are related to
symptomatic infection, wasting, mild abdominopelvic problems and anemia [1, 3].
The World Health Organization (WHO) recommends large-scale, periodic distribution of
safe and efficacious anthelminthic drugs as preventive chemotherapy (PC) to at-risk popula-
tions in endemic areas for morbidity control of STH infections [4, 5]. PC allows a reduction of
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infection intensities from heavy or moderate to light, hence preventing morbidity, rather than
curing infection and/or interrupting transmission [5]. The groups at highest risk of STH infec-
tion-related morbidity are children, who are in a critical phase of growth and development,
and women of childbearing age, including pregnant women, who have increased nutritional
requirements during pregnancy and lactation [6].
Currently, STH infections are treated predominantly with the two benzimidazole drugs
albendazole (400 mg) or mebendazole (500 mg) [7]. A meta-analysis published in 2017 showed
that both drugs are highly efficacious against A. lumbricoides (cure rate (CR) = 96% with alben-
dazole and CR = 96% with mebendazole), but less efficacious against hookworm (CR = 80%
with albendazole and CR = 33% with mebendazole), and even less against T. trichiura
(CR = 31% with albendazole and CR = 42% with mebendazole) [8]. Thus, it is crucial to
increase efforts to explore alternative therapies to both increase efficacy for trichuriasis and
delay the emergence of potential drug resistance in view of the massive drug pressure exerted
by widespread use and dependence of these two drugs.
An additional anthelminthic drug, ivermectin, has been used widely in humans, either
alone against onchocerciasis or in combination with albendazole against lymphatic filariasis
(LF) since the late 1980s [7, 9]. This drug has played a key role in the elimination programs of
these two NTDs [4]. In 2015 alone, more than 50 million school-aged children received iver-
mectin in addition to albendazole within the global program to eliminate LF [10]. It is not
clear, however, how the LF program translates into clearing and/or reducing the intensity of
STH infections [11]. There is indirect evidence of reduced STH burden in areas where alben-
dazole and ivermectin have been co-administered [12]. While ivermectin alone is considered
to have suboptimal efficacy against hookworm and T. trichiura infections [13–17] there are
data indicating that the co-administration of ivermectin and albendazole can be more effica-
cious than single-drug regimens [18–20]. The co-administration of ivermectin and albenda-
zole was therefore recently added to the WHO Essential Medicines List for the treatment of
STH infection [21].
We conducted, for the first time, a systematic review and meta-analysis of the efficacy and
safety of the co-administration of albendazole plus ivermectin compared to albendazole alone
for treating STH infections. Post-treatment reactions are often related to disease triggered by
parasite death [22] and it is thus important to know whether the tolerability is comparable in
STH and LF infections. Furthermore, we analyzed efficacy measures based on individual
patient data from three recent randomized controlled trials (RCTs). Our findings will help to
inform improved treatment guidelines for STH infections.
Methods
Protocol and registration
The protocol of this systematic review, which is provided as a supplementary file (S1 File), was
recorded and published in the International Prospective Register of Systematic Reviews
(PROSPERO) online database, number CRD42017060710 (S2 File). The review and meta-
analysis were conducted according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement [23]. Reporting according to PRISMA guidelines are
summarized in the checklist provided as a supplementary file (S3 File).
Efficacy information sources and search strategy
A literature search without language restriction was performed in PubMed, ISI Web of Science
and Science Direct (from 1960 to January 24, 2018) to identify clinical trials pertaining to the
use of ivermectin in combination with albendazole for treating hookworm, A. lumbricoides
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and T. trichiura. The search terms included: “ivermect [AND] albendaz [AND] (hookworm
[OR] trichuri [OR] ascari [OR] soil-transmitted helminth) [AND] (cure [OR] trial)”.
Additionally, we performed a search using the keywords “ivermectin” and “albendazole” in
the following databases and online repositories: Cochrane Central Register of Controlled Trials
(CENTRAL) and ClinicalTrials.gov maintained by the National Library of Medicine (NLM) at
the National Institutes of Health (NIH). The search strategy is detailed in supplementary file
(S1 Text).
Individual patient data on efficacy of ivermectin combined with albendazole against STH
infections from three published trials [18, 20, 24] were obtained through personal communica-
tion and were subjected to further in-depth analysis.
Safety information sources and search strategy
To identify safety data from the co-administration of ivermectin and albendazole, a literature
search was performed using databases from PubMed, ISI Web of Science and Science Direct
(from 1960 to January 24, 2018) applying the following search terms: “ivermect [AND] alben
[AND] combin [AND] (adverse [OR] side effect [OR] symptom)”. No restrictions with
regard to language, parasite species or study type were applied. Likewise to efficacy, we addi-
tionally searched the online databases and repositories of CENTRAL and ClinicalTrials.gov
for documentations on safety using the keywords “ivermectin” and “albendazole” (S1 Text).
Eligibility criteria
All retrieved references were screened by title and abstract for efficacy and safety information
on ivermectin-albendazole co-administration in humans using the eligibility criteria detailed
below. From the studies assessing efficacy, we selected RCTs, which tested the co-administra-
tion of ivermectin and albendazole against at least one STH (hookworm, T. trichiura and/or A.
lumbricoides). We included only studies which administered the standard doses of the drugs
(ivermectin: 200 μg/kg; albendazole: 400 mg) as recommended by the Essential Medicine List
[21], and which assessed drug efficacy (follow-up survey) between 7 days and six weeks post-
treatment. According to WHO, follow-up assessment of drug efficacy should take place
between two and three weeks post-treatment because reinfection is common and long follow-
up periods may prevent a clear distinction between poor efficacy and new infections [25].
However, to be more inclusive, we extended this period from 7 days to six weeks. The diagnos-
tic method used in the studies was not part of the selection criteria.
The main eligibility criterion for potentially relevant studies on safety was reporting of any
quantitative or qualitative data of adverse events (AEs) following administration of ivermectin
in combination with albendazole in any clinical trial. Sample size varied among studies but
was not considered as an inclusion/exclusion criterion. Case studies from medical reports
were not considered due to non-representativeness of outcomes. Data published in reviews
were included if they had not been identified in our literature search already. Additional rele-
vant studies on safety identified through reviews or online repositories and not yet covered
through the literature search were subsequently included. Due to the non-standardized
approach to reporting safety information, we expanded the search to include different doses
and different time points of AE assessment and follow-up (vs. efficacy for which there is a stan-
dardized approach recommended by WHO).
Risk of bias within and across included studies
The quality and risk of bias of eligible efficacy studies was assessed at study level using the
Cochrane risk of bias tool [26]. The assessment was based on six items included in the bias
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assessment tool: random sequence generation, allocation concealment (both define the selec-
tion bias), blinding of participants and personnel (performance bias), blinding of outcome
assessment (detection bias), incomplete outcome data (attrition bias) and selective reporting
(reporting bias). Each study was rated, for each of the items, as “high risk” or “low risk” of bias
based on the criteria for judging risk of bias. If the study did not report sufficient detail to con-
sider “high risk” or “low risk”, the risk of bias was classified as “unclear risk”.
For safety studies included in the meta-analysis the same Cochrane training tool for quality
assessment was applied as detailed above. As there were fewer than 10 studies in each of the
meta-analysis, the risk of bias across studies could not be assessed, as recommended by Sterne
et al. (2011) [27].
Data extraction
All references fulfilling the eligibility criteria were subjected to data extraction in duplicate by
two independent reviewers (MSP and EH). For each study information on the publication (i.
e., authors and year), general study-specific data such as type of study, country where the study
took place, parasite species, participant data (i.e., age group, number of individuals), follow-up
period and data collection method (i.e., repeated stool sampling for efficacy, passive vs. active
surveillance for safety) was retrieved.
For studies assessing efficacy, the main outcomes were the number of treated and infected
participants (before and after treatment), CRs (the percentage of individuals who became hel-
minth egg negative following treatment) and egg reduction rates (ERRs) (when available).
Number of AEs and specific reported symptoms (if detailed), type of AEs (i.e., symptom,
observable or lab event) and whether AEs were associated with baseline parasite infection sta-
tus were recorded for appraisal of safety data. If AE data were provided as number of partici-
pants with AEs and number of AEs, respectively, the earlier was preferred for data extraction.
Statistical analysis
Analysis of efficacy aggregate data. For the meta-analysis, we used the open-source ver-
sion of R (version 3.4.3.) using RStudio (version 1.0.143)[28]. Forest plots were performed
using the forest command of R. Heterogeneity of datasets within the meta-analysis was quanti-
fied using I2 and random-effects models were performed to account for the heterogeneity
between studies. The CRs and ERRs extracted from the selected publications were used to
describe differences in efficacy performance. We used risk ratio’s (RRs) for the failure rate as
an estimate of the true risk of being still infected after treatment in each treatment arm. A
RR<1 indicates a lower risk of remaining infected when treated with the combination of iver-
mectin and albendazole compared to being treated with albendazole alone. A RR = 1 shows
the risk of still being infected after treatment is the same in both groups. A RR>1 indicates
that subjects in the albendazole alone group are at lower risk of still being infected.
Analysis of individual patient efficacy data. All individual patient data analyses were
conducted using SAS system version 9.4 (SAS Institute, Cary, NC, United States of America).
Individual patient’s egg counts at baseline and post-treatment were transformed in eggs per
gram (EPG) of stool by multiplying the arithmetic mean (AM) number of eggs per Kato-Katz
slide by 24. The AM EPG was calculated at baseline for each parasite species, study and treat-
ment group within study.
Drug efficacy was expressed as ERR and CR. Individual ERR was calculated as the ratio of
the difference between the pre- and post-treatment EPG to the pre-treatment EPG multiplied
by 100 for each patient. Negative individual ERRs were classified as zero. The CRs and 95%
binomial confidence intervals (CIs) were calculated as the percentage of STH infected
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individuals at baseline who turned negative at follow-up. The distribution of individual
responses in egg excretion was expressed in centiles to quantitate the fraction of poor respond-
ers and plotted cumulatively. Both no change and an increase in EPG between pre- and post-
treatment were considered as ERR = 0.
A linear model was used to evaluate the effects of treatments on the individual ERR for each
STH (A. lumbricoides, T. trichiura and hookworm). The models accounted for clustering on
study level and were adjusted for patient-level factors such as age, number of species observed
in the stools and the log-transformed baseline EPG. Marginal means of ERR for each treatment
were predicted from the model and compared pairwise with a Tukey adjustment for multiplic-
ity. All tests were two-tailed; a p-value of 0.05 was deemed significant.
Analysis of aggregate safety data. Safety data from relevant publications were summa-
rized using mainly descriptive statistics assessing frequencies of reported AEs and specific
symptoms in co-treated participants, where applicable. The number of AEs per group and rela-
tive risk among studies comparing co-administered ivermectin and albendazole with single
doses of albendazole or ivermectin alone were analysed applying a between-study meta-analy-
sis as done for the efficacy data. Additionally, a sub-group meta-analysis was performed by fur-
ther stratifying infection status of the respective study participants by parasitic disease (i.e. LF
and/or onchocerciasis vs. STH). Studies not explicitly stating quantitative data on AEs and
symptom reporting among co-treated individuals but providing valuable information on
safety parameters were retained for qualitative appraisal.
Results
Literature search on efficacy data and study characteristics
Among the six potentially relevant studies identified, two [29, 30] were excluded because they
did not use the recommended doses of ivermectin and/or albendazole (albendazole: 400 mg,
ivermectin: 200 μg/kg) (Fig 1, Table A in S2 Text). As a result, we selected a total of four stud-
ies, of which one compared the co-administration of ivermectin-albendazole to albendazole
and ivermectin alone [18], two compared the co-administration to albendazole alone [19, 20]
and one compared ivermectin-albendazole to other therapies which were not considered in
this review (Fig 1) [24]. The features and methodological quality of the selected studies are
summarized in Fig 2. The more recent trials [20, 24] reported more methodological details on
the study design and measures for mitigation of potential bias and thus reached higher quality
levels than the older ones [18, 19].
Table 1 provides a brief overview on the four selected RCTs and their characteristics.
Note that not all studies evaluated the efficacy of the drugs against all STHs: Ismail et al.
[19] only assessed the efficacy against T. trichiura and Belizario et al. [18] did not evaluate
efficacy against hookworms. The treatment outcome in all four selected studies was assessed
between 7 and 39 days post-treatment (2/4 studies at +/- 21 days). This assessment was
done by examining one or two stool samples. Two studies collected one sample, one of
these studies does not report on how many slides were performed from the stool sample
[19] and the other performed duplicate Kato-Katz thick smears [18]; the other two studies
collected two samples and performed duplicate Kato-Katz thick smears on each one [20,
24].
Table 2 summarizes the efficacy outcomes of each single and the combined drug regimen
investigated against the different STH species in all four studies. Outcome measures were CRs
and ERRs–calculated using geometric means in all four studies. The first three studies in
Table 2 show an improvement of the CR against T. trichiura when using the combination of
ivermectin-albendazole vs. ivermectin or albendazole alone.
Ivermectin-albendazole for soil-transmitted helminths: Systematic review and meta-analysis
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Comparison of efficacy outcomes between single-drug and combined
treatment for each STH species
Efficacy against T. trichiura infections. The CRs and ERRs of the four studies evaluating
the efficacy against T. trichiura are presented in Table 2. For the three studies comparing iver-
mectin-albendazole to albendazole alone (n = 342 and n = 336 patients, respectively), the
aggregated-data meta-analysis is presented as a forest plot in Fig 3. The co-administration of
ivermectin-albendazole was significantly more effective than albendazole alone at clearing T.
trichiura infection, with a RR for still being infected post-treatment of 0.44 (95% CI = 0.31–
0.62). While no bias indicators could be calculated since there were too few strata, all three
studies favored the co-administration over single-agent albendazole. In the same three selected
studies, patients treated with the co-administration had ERRs ranging from 91% to 100% for
T. trichiura which is considerably higher than those for albendazole alone ranging from 40%
to 97% (Table 2). Although they did not compare to either drug alone, Speich et al. (2015) [24]
found a CR of 28% and an ERR of 95% using the co-administration of ivermectin and albenda-
zole (Table 2). Belizario et al. [18] reported that the efficacy of the co-administration of iver-
mectin-albendazole was also higher than that of ivermectin alone (CR = 65% vs. CR = 35%,
respectively) (Table 2).
Fig 1. PRISMA flowchart showing the selection process of the efficacy and safety studies.
https://doi.org/10.1371/journal.pntd.0006458.g001
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The analysis of the individual patient data led to similar results, i.e. individual ERRs of
100% were significantly more often achieved with the co-administration of ivermectin and
albendazole than with the administration of albendazole alone (mean individual ERR = 94.9%,
95% CI = 90.9–97.1% vs. mean individual ERR = 49.3%, 95% CI = 6.7–81.1%, respectively;
Fig 2. Quality assessment of included efficacy randomized controlled trials using the Cochrane criteria [26] for judging risk of bias. Note:
+ = low risk, - = high risk, ? = unclear.
https://doi.org/10.1371/journal.pntd.0006458.g002
Table 1. Treatments administered by each study and respective study characteristics for included efficacy studies.
Reference
no.
Study IVM
+ ALB
ALB alone (or with
placebo)
IVM alone (or with
placebo)
Country Studied
parasites
Follow-up
period
Age
group
No. stool
samples
[18] Belizario et al.,
2003
X X X Philippines T. trichiura
A. lumbricoides
7–14 days 6–12 1 at baseline
1 at follow-up
[19] Ismail et al.,
1999
X X Sri Lanka T. trichiura 3 weeks 4–14 1 at baseline
1 at follow-up
[20] Knopp et al.,
2010
X X Tanzania T. trichiura
A. lumbricoides
Hookworm
22–39 days 6–20 2 at baseline
2 at follow-up
[24] Speich et al.,
2015
X Tanzania T. trichiura
A. lumbricoides
Hookworm
18–23 days 6–14 2 at baseline
2 at follow-up
Note: IVM + ALB = co-administration of ivermectin-albendazole, ALB = albendazole, IVM = ivermectin.
Speich et al. 2015 [24] compared ivermectin-albendazole to albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole alone.
https://doi.org/10.1371/journal.pntd.0006458.t001
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p<0.05) (Fig 4). 78.9% of the Trichuris-infected individuals in the single albendazole arms
from the pooled individual data sample revealed an ERR below 100%, compared to 54.2% of
those in the co-administration as shown in the cumulative percentage curve. This would trans-
late into a CR of 21.1% and 45.8%, respectively, for single and ivermectin-co-administered
albendazole. The proportion of subjects who did not respond to treatment (ERR = 0) was 8%
with the combination vs. 24% with albendazole alone. When the overall ERRs for each treat-
ment arm were considered, both ivermectin alone (ERR = 72.1%) and ivermectin-albendazole
co-administered (ERR = 84.5%), performed significantly better than albendazole alone
Table 2. Efficacy measures (i.e. cure rates (CRs) and egg reduction rates (ERRs)) by treatment arm against each soil-transmitted helminth species.
Study Efficacy
parameter
T. trichiura A. lumbricoides Hookworm
N IVM + ALB
(95% CI)
ALB alone
(95% CI)
IVM alone
(95% CI)
N IVM + ALB
(95% CI)
ALB alone
(95% CI)
IVM alone
(95% CI)
N IVM + ALB
(95% CI)
ALB alone
(95% CI)
IVM alone
(95% CI)
Belizario
et al., 2003
CR 452 65% 32% 35% 306 78% 70% 78% - - - -
ERR 100% 97% 98% 100% 100% 100%
Ismail et al.,
1999
CR 108 81% 44% - - - - - - - - -
ERR 95% 70%
Knopp et al.,
2010
CR 303 38%
(29.8–46.4)
10%
(5.4–16.3)
- 34 93% 100% - 81 67% 59% -
ERR 91%
(87.2–94.0)
40%
(21.5–
55.7)
100% 100% 96% 94%
Speich et al.,
2015
CR 110 28%
(19.0–36.0)
- - 50 98%
(94.0–100)
- - 43 50%
(34.2–65.8)
- -
ERR 95%
(91.7–96.3)
100%
(99.9–100)
96%
(90.8–98.3)
Note: IVM + ALB = co-administration of ivermectin-albendazole, ALB = albendazole, IVM = ivermectin. Not all studies provided 95% confidence intervals (CIs).
Speich et al. 2015 [24] compared ivermectin-albendazole to albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole alone.
https://doi.org/10.1371/journal.pntd.0006458.t002
Fig 3. Forest plot displaying the results of a random-effects meta-analysis of aggregated data of the effect of the co-administration of ivermectin-albendazole on
the number of patients infected with T. trichiura compared to albendazole alone.
https://doi.org/10.1371/journal.pntd.0006458.g003
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(ERR = 59.1%) (p<0.001). The comparison of ivermectin alone and the combined treatment
was significantly in favor of the latter (p<0.001). While ivermectin alone had slightly fewer
ERRs of 0% than the ivermectin-albendazole combination treatment, the latter outperformed
the single drug treatment with higher proportions of infection clearance (i.e. ERR = 100%).
Efficacy against A. lumbricoides infections. As there were only two studies comparing
the efficacy of the co-administration of ivermectin-albendazole vs. albendazole and ivermectin
alone against A. lumbricoides infection, a meta-analysis could not be performed. Both studies
showed comparable CRs among treatments and ERRs of 100% for both the single-agent and
the combination arm. The individual patient data analysis also did not reveal any advantage of
including ivermectin against A. lumbricoides (Fig 5) with summary ERR estimates of 98.4%
(albendazole, 95% CI = 93.8–100.0%) vs. 98.6% (ivermectin-albendazole, 95% CI = 94.7–
100.0%) (p = 0.993).
Efficacy against hookworm infections. A single study compared the efficacy of ivermec-
tin-albendazole vs. albendazole alone against hookworm infections [20]. The co-administra-
tion produced an only marginally higher CR and a similar ERR than albendazole alone
(Table 2) [20]. The individual patient data analysis, that also included the hookworm infec-
tions treated with the co-administration from the study by Speich et al. (2015) [24] did not
reveal any significant difference in efficacy between the two treatments against hookworm
with ERRs of 81.7% vs. 78.0%, respectively (p = 0.643) (Fig 6).
Fig 4. Proportional distribution (A) and cumulative centile curve (B) of individual egg reduction rates (ERRs) in T. trichiura-infected individuals (n = 845) by
treatment arm.
https://doi.org/10.1371/journal.pntd.0006458.g004
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Results from the literature search on safety data and study characteristics
A total of 665 records were identified using the described search strategy (see S1 Text). These
articles were screened for safety data on the co-administration of albendazole and ivermectin.
In total, 32 studies were retained and full-text articles checked on eligibility criteria as defined
above (see Fig 1). Details on study characteristics and reasons for inclusion or exclusion are
provided as a supplementary file (Table B in S2 Text). Six studies were excluded due to non-
extractability of the data or missing relevant information (n = 3) [18, 31, 32], consecutive
instead of co-administration of ivermectin and albendazole (n = 2) [16, 33] and one study
additionally administered diethylcarbamazine (DEC) together with the ivermectin-albenda-
zole combination (n = 1) [34]. A total of 26 studies were included and considered for quantita-
tive or qualitative appraisal in this review. Among these, 24 provided quantitative information
on AEs (Table 3) of which 22 detailed specific information on symptoms (Table 4). One review
[35] served as a supplementary quantitative and qualitative information source to complement
data from included original research articles. Another study provided description of AEs with
regard to pregnancy outcome [36]. All studies with quantitative data that provided the actual
number of AEs, the total number of treated individuals in the co-administered ivermectin-
albendazole group and that had at least one single drug comparator (albendazole or ivermec-
tin) group were selected for further analysis by means of meta-analysis (n = 5) (Table 3).
Fig 5. Proportional distribution (A) and cumulative centile curve (B) of individual egg reduction rates (ERRs) in A. lumbricoides-infected individuals (n = 385) by
treatment arm.
https://doi.org/10.1371/journal.pntd.0006458.g005
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Studies with zero AEs in all groups [37, 38] or less than five individuals per treatment arm [39]
were not considered.
The quality and types of potential biases of these five studies is summarized in Fig 7. Two
studies reached the highest quality grading [20, 40], while one did not clearly state about blind-
ing of outcome assessors [41] and two studies followed an open-label or only partly blinded
study design [30, 42], provided incomplete information on random allocation measures and
thus reached lower grading.
Among the included safety studies providing original quantitative information on treated
subjects (n = 24), the number of monitored individuals after treatment administration varied
considerably and mainly depended on study type and design (Table 3, Table B in S2 Text).
Twenty one studies were clinical trials of which the majority (n = 16) applied an active surveil-
lance approach and more than half (n = 12) were RCTs. Four studies reported safety parame-
ters assessed either using an observational [46, 48, 57] or a trial design (including comparison
between matched groups) [45] embedded in regional or national control programs applying
mass drug administration (MDA) against LF. Thus, these four studies had much larger sample
sizes.
Within the trials, most studies involved participants with filariasis such as LF due to
Wuchereria bancrofti (n = 7) [41, 43, 49, 50, 54–56] or Brugia malayi (n = 2) [39, 53], onchocer-
ciasis due to Onchocerca volvulus (n = 1) [40], mansonellosis due to Mansonella perstans
(n = 2) [37, 38] or co-infections of the above (n = 3) [42, 47, 51]. Three studies assessed the
Fig 6. Proportional distribution (A) and cumulative centile curve (B) of individual egg reduction rates in hookworm-infected individuals (n = 117) by treatment arm.
https://doi.org/10.1371/journal.pntd.0006458.g006
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safety of ivermectin-albendazole co-administration in patients infected with STHs [20, 24, 30]
and one study in patients with schistosomiasis caused by Schistosoma haematobium and/or S.
mansoni [45]. Two studies assessed the safety of co-administered ivermectin and albendazole
in healthy subjects [44, 52]. Trials were conducted in ten different countries whereas observa-
tional data after MDA campaigns was available for 5 countries. Of the 21 trials, eight were
from East Africa (Malawi, Tanzania and Uganda), seven from West Africa (Ghana and Mali),
Table 3. Studies reporting quantitative data for adverse events (AEs) after ivermectin-albendazole co-administration (n = 24).
Reference
no.
Study Study type Country Disease
(parasite)
IVM+ALB IVM ALB
No.
treated
No.
AEs
No.
treated
No.
AEs
No.
treated
No.
AEs
[43] Addis et al., 1997 Trial (RCT) Haiti wb 44 NR 43 NR 27 NR
[44] Amsden et al., 2007 Trial (open) USA healthy 18 1 - - - -
[45] Anto et al., 2011 Trial (matched) Ghana sh, sm, (wb,
onc)
15552 130 - - - -
[37] Asio et al., 2009a Trial (matched) Uganda mp 15 0 15 0 13 0
[38] Asio et al., 2009b Trial (RCT) Uganda mp 86 0 96 0 - -
[40] Awadzi et al., 2003$ Trial (RCT) Ghana onc 14 14 14 11 14 13
[46] Coulibaly et al., 2015 prospective cross-
sectional
Mali wb 2135 13 - - - -
[47] Dembele et al., 2010† Trial (RCT) Mali wb, mp 42 9 - - - -
[41] Dunyo et al., 2000 Trial (RCT) Ghana wb 332 47 295 36 336 31
[48] Hodges et al., 2010 MDA post-
treatment reporting
Sierra Leone wb 1104407 146 - - - -
[49] Ismail et al., 1998 Trial (blinded) Sri Lanka wb 13 NR - - 12 NR
[50] Ismail et al., 2001# Trial (blinded) Sri Lanka wb 31 NR - - - -
[51] Keiser et al., 2003 Trial (blinded) Mali wb, mp 40 11 - - - -
[20] Knopp et al., 2010 Trial (RCT) Tanzania (Unguja island) tri 144 64 - - 136 60
[42] Makunde et al.,
2003
Trial (RCT) Tanzania (mainland) wb, onc 20 11 - - 13 5
[52] Na-Bangchang et al.,
2006
Trial (open) Thailand healthy 23 0 - - - -
[30] Ndyomugyenyi
et al., 2008
Trial (RCT) Uganda sth 199 8 198 24 194 16
[39] Shenoy et al., 1999 Trial (open) India bm 16 12 - - 3 2
[53] Shenoy et al., 2000 Trial (open) India bm 12 6 - - - -
[54] Simonsen et al., 2004 Trial (RCT) Tanzania (mainland) wb 586 NR - - 635 NR
[24] Speich et al., 2015 Trial (RCT) Tanzania
(Pemba island)
tri 108 22 - - - -
[55] Tafatatha et al., 2015 Trial (RCT) Malawi wb 70 22 - - - -
[56] Turner et al., 2006 Trial (RCT) Ghana wb, wbb 28 20 - - - -
[57] WHO, 2003 MDA post-
treatment reporting
Burkina Faso, Nigeria, Tanzania
(Mafia & Zanzibar islands)
lf 9831 2358 - - - -
$No. of AEs based on positive vs. zero Mazzotti reaction scores.
†Two different schemes of IVM/ALB combination: 150 μg/kg+400 mg (n = 22) and 400 μg/kg+800 mg (n = 20)
#Two different schemes of IVM/ALB combination: 200 μg/kg+400 mg (n = 16) and 400 μg/kg+600 mg (n = 15).
No. of AEs instead of no. of participants with AEs.
Disease (parasite) abbreviations: bm = Brugia malayi, lf = lymphatic filariasis (species not specified), mp = Mansonella perstans, onc = Onchocerca volvulus, sh =
Schistosoma haematobium, sm = Schistosoma mansoni, sth = soil-transmitted helminths, tri = Trichuris, wb = Wuchereria bancrofti, wbb = Wolbachia bacteria
RCT = randomized controlled trial, NR = not reported: no overall number of patients with AEs or AEs itself provided, AE frequencies only given for specific symptoms.
Studies in bold were subjected to meta-analysis.
https://doi.org/10.1371/journal.pntd.0006458.t003
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five from South-East Asia (India, Sri Lanka and Thailand), one from Latin America and the
Caribbean (Haiti) and one from North America (USA). Post-MDA-treatment safety reporting
was available for West Africa (Burkina Faso, Mali, Nigeria and Sierra Leone) and East Africa
(Tanzania).
Most common adverse events. Table 4 provides a detailed overview on all different types
of AEs reported after co-administration of ivermectin and albendazole. There is a marked
imbalance in terms of population size and reporting methodology between the two observa-
tional studies (which followed up 1,104,407 and 9831 patients treated with the combination
therapy respectively) [48, 57] and the other studies (which collectively enrolled 17,314
patients). The latter only reported AEs for the co-administration of ivermectin-albendazole,
which were mild or moderate in severity. The observational studies on the other hand reported
1 and 151 severe AEs, respectively, but none was considered as a serious adverse event (SAE).
Headache, fever, abdominal pain, muscle/joint pain and allergic reactions like pruritus and
rashes ranked among the top five symptoms assessed by these studies. Fever and headache
Fig 7. Quality assessment of included safety studies using the Cochrane criteria for judging risk of bias. Note: + = low risk,— = high risk, ? = unclear. Study
including two groups with different designs: W. bancrofti-single-infected group = open design, W. bancrofti/O. volvulus-co-infected group = double blind design.
https://doi.org/10.1371/journal.pntd.0006458.g007
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were the most frequent AEs. Abdominal pain was prominently reported in trials of intestinal
helminthiases [20, 24, 30, 45] and muscle/joint pain together with skin reactions (e.g. pruritus
and rashes) were more often observed in studies of filariasis [41–43, 48]. Laboratory events
were rarely reported; there were altogether 8 cases of increased levels of liver enzymes [49, 52,
58] that usually returned to normal levels within few weeks.
Safety of ivermectin-albendazole compared to albendazole alone. Five RCTs compared
the safety of co-administered ivermectin and albendazole to albendazole alone. Fig 8 shows the
results from the random-effects meta-analysis from all studies pooled as well as stratified by
parasitic infection type (filariasis vs. soil-transmitted helminthiasis). The overall estimate
shows an RR of 1.09 (95% CI = 0.87–1.36) for AEs in the co-administration group vs. albenda-
zole alone. When stratified by helminthic disease, the RR for patients with filariasis (i.e., LF
and onchocerciasis) was 1.29 (95% CI = 0.81–2.05), and 0.78 (95% CI = 0.39–1.56) for STH in
co-treated compared to albendazole-alone treated patients. None of these comparisons was
statistically significantly different.
Safety of ivermectin-albendazole compared to ivermectin alone. Three of the five stud-
ies included in the meta-analysis also compared the co-administration to single ivermectin
administration, with inconsistent results: Awadzi et al. [40] and Dunyo et al. [41] reported
slightly more AEs in the combination arm, while the opposite result was demonstrated by
Ndyomugyenyi et al. [30]. Consequently, no statistical difference in the number of AEs was
found in the meta-analysis model (RR = 0.86, 95% CI = 0.41–1.80) as shown in Fig 9.
Fig 8. Forest plots showing random-effects meta-analysis of the number of patients with adverse events (AEs) after co-administration of ivermectin-albendazole
compared to albendazole alone stratified by helminthic disease. RE = random effects. NA = not applicable, RE = random effects.
https://doi.org/10.1371/journal.pntd.0006458.g008
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Additional outcomes and factors associated with safety. Two studies explored the rela-
tionship between co-administration of ivermectin and albendazole and pregnancy outcome.
There was no evidence of a higher risk of congenital malformation or abortions (spontaneous
or miscarriages) due to treatment. Moreover, there was no significant association between
treatment and the proportion of newborns with low birth weight or congenital abnormalities
and the number of stillbirths [30, 36].
No difference in safety was observed between low- and high dose ivermectin-albendazole
formulations within the same trials [47, 55, 58].
As highlighted in Table 4, nine studies observed direct relationships between the baseline
microfilariae levels and the number and intensity of AEs. Of these, eight were related to W.
bancrofti infections and one to O. volvulus. This latter study used the Mazzotti score to distin-
guish between the reaction to the killing of microfilariae and direct drug-related AEs [40].The
relationship between parasite death and number of AEs is further supported by the two studies
assessing the efficacy and safety in M. perstans infection. The combination therapy showed no
effect on Mansonella microfilariae levels and not a single AE was reported [37, 38].
Finally, study design and the method of assessing safety (e.g. active vs. passive reporting)
may also influence the extent of reported, observed or measured events. Passively assessed tar-
get populations revealed lower numbers of AEs compared to intensively monitored partici-
pants within RCTs or large-scale active surveillance reports (Table 4). Furthermore, it is
important to take into account the baseline symptomatology or clinical indicators such as
hematological or metabolic parameters when symptom reports or laboratory events are con-
sidered for AE assessment (treatment-emergent adverse events, TEAE). Nine studies
Fig 9. Forest plot showing random-effects meta-analysis of the number of patients with adverse events after co-administration of ivermectin-albendazole
compared to ivermectin alone.
https://doi.org/10.1371/journal.pntd.0006458.g009
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considered any kind of pre-treatment parameters (e.g. self-reported symptoms or clinical indi-
cators). Of these, three showed an increase from baseline values [40, 49, 56], four reported no
difference [37, 42, 44, 52], one only used the pre-treatment parameters as exclusion criteria
[51] and one study observed reduced symptom reporting compared to baseline in the ivermec-
tin-albendazole co-administration arm [24].
Discussion
Infections with STH continue to be amongst the most common infections worldwide and PC
is the main strategy applied for morbidity control [4]. PC relies mainly on two benzimidazole
drugs (albendazole and mebendazole) but they are not equally efficacious against all three hel-
minths; T. trichiura remains the main challenge [8, 62].
To our knowledge, this is the first systematic review and meta-analysis exploring the effi-
cacy and safety of the co-administration of ivermectin and albendazole against STH infections.
Both our aggregate and individual patient data analysis indicate that the co-administration of
ivermectin and albendazole is more effective against T. trichiura than either of the drugs alone.
The co-administration does not seem to offer advantages over albendazole alone on either
hookworm or A. lumbricoides.
The inclusion of ivermectin-albendazole co-treatment in the WHO Model List of Essen-
tial Medicines to treat STH is likely to promote its roll-out in future MDA campaigns [21].
From our findings one can, therefore, anticipate that this will provide enhanced efficacy
in T. trichiura-infected individuals (the most difficult-to-treat STH infection [8, 62]).
Although not evaluated in the present review, the albendazole-ivermectin co-administra-
tion would also benefit Strongyloides stercoralis-infected individuals [63, 64]. On the other
hand, the decrease of PC for LF represents a risk of losing ancillary benefit for soil-transmit-
ted helminthiasis control in the framework of the Global Programme to Eliminate Lym-
phatic Filariasis (GPELF). In more detail, in 2015, 52 million school-aged children received
albendazole-ivermectin in this program in STH co-endemic areas [10]. With decreasing PC
for LF, effective transitions are required to cover the lost contribution of the GPEFL pro-
gram for STH control.
It is worth highlighting that coverage and compliance of target populations are essential for
the successful future roll-out of integrated treatment of ivermectin and albendazole against
STH infections. Knowledge about MDA programs and its efficacy against the target disease
together with appropriate handling of potential safety issues by MDA implementation staff has
been shown to positively influence the target populations’ acceptance of ivermectin-albenda-
zole treatment campaigns against LF [65]. However, LF programs only target children aged
five years or above meaning all preschool-aged children have not been receiving ivermectin-
albendazole. As the official target age group of STH control includes preschool-aged children,
it would be of great value to study both efficacy and safety of this combination in this age
group. Of note, a recent study evaluated for the first time the efficacy and safety of ivermectin
in preschoolers infected with T. trichiura and demonstrated that the drug can be safely used in
young children [17].
With more than 20 studies reporting safety-relevant information, this systematic review
helps to better define the tolerability profile of the co-administration of ivermectin and alben-
dazole covering not only soil-transmitted helminthiasis but also filariasis. Overall, the co-
administration was well-tolerated and caused only mild and transient AEs. While study design,
size and methods for assessing safety varied across these studies, collectively they covered a
range of patient populations (including adult men, pregnant women and schoolchildren) and
diseases (from healthy individuals to those with soil-transmitted helminthiasis or filariasis).
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When considering the five RCTs comparing single- and co-treated patients, we found no
difference in the incidence of AEs between ivermectin plus albendazole vs. albendazole or iver-
mectin alone. Of note, among the five studies included in our review, two were on STH treat-
ment [20, 30] and three on another indication [41–43]; when stratifying by type of infection,
we found no difference in STH-infected subjects between albendazole and ivermectin plus
albendazole, compared to a slightly higher incidence of AEs in filariasis patients treated with
ivermectin plus albendazole, which appears to be mostly related to Mazzotti-type reactions (i.
e. caused by the effects of treatment of microfilariae).
A common problem when assessing safety in clinical trials is that they tend to report the
incidence of AEs on treatment disregarding their presence and intensity before treatment.
Here, we identified eight studies which took into account pre-treatment symptoms and clinical
parameters; among these only three (all in filariasis) showed increased numbers of AEs com-
pared to the baseline status in co-treated patients [40, 49, 56].
The main limitation of this systematic review is the very low number of published RCTs on
the efficacy (n = 4) and safety (n = 5) of ivermectin-albendazole compared to albendazole or
ivermectin alone, which meant we could only conduct a meta-analysis on T. trichiura infec-
tions, but not on the other two STH species. Sub-group analysis (e.g. by population strata, level
of baseline worm burden, parasitic disease for safety data) was also either not possible or
inconclusive with such low numbers of studies. While our meta-analysis focused on the risk of
still being infected after treatment, a future analysis, once more data from upcoming studies
will be available, could consider using mixed linear models for analyzing egg reduction rates, a
key parameter for assessing anthelminthic drug efficacy. The low number of eligible studies
also prevented us from evaluating the possibility of publication bias [27] or heterogeneity for
certain sub-groups. Moreover, the included studies revealed several shortcomings. Of the four
studies selected to summarize overall efficacy, two [20, 24] presented low risk of bias as per the
Cochrane risk of bias tool but the remaining two studies [18, 19] were not double-blinded and
did not report on several procedures. Moreover, two of the included studies [18, 20] did not
adhere to the recommended follow up time point 2–3 weeks post-treatment [66]. Finally,
within the five safety-related studies eligible for the meta-analysis, three reached acceptable
quality levels with at least five out of the six bias indicators considered as “low risk”.
It is therefore obvious that our findings need to be confirmed through high-quality research
studies with a rigorous design (e.g. single- or double-blinded RCTs). Furthermore, it is impor-
tant to produce evidence from different settings in terms of parasite and target populations.
The main STH species plus S. stercoralis may show different drug susceptibility in different
endemic areas potentially also related to different levels of drug pressure in populations to be
treated (e.g. MDA naïve vs. experienced populations) [67, 68]. These studies could also evalu-
ate the long-term benefit and different treatment schedules of this co-administration, compare
ivermectin-albendazole to other co-administration treatments, which have emerged over the
past years [69], to inform treatment guidelines and strategic planning of STH control, as well
as monitoring and evaluation. Along with efficacy, future studies must assess safety in the
same rigorous manner. The safety review suggests that AEs of ivermectin-albendazole may be
more common in populations with filariasis. Since filariasis and soil-transmitted helminthiases
often co-exist [70], future studies must take into account filariasis either by excluding co-
endemic areas or by diagnosing both diseases.
Conclusions
Our results suggest that the co-administration of ivermectin and albendazole increases efficacy
against T. trichiura, but most likely has no gain against A. lumbricoides and hookworm. Safety
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reports were very diverse in study design, target population and treatment indication but in
summary confirmed its tolerability with mostly mild and transient AEs. Together, these find-
ings support the recent WHO recommendations and inclusion in the WHO Model List of
Essential Medicines. At the same time, they also point to the need for additional and more reli-
able information through well-conducted studies in the different contexts where the co-
administration is to be deployed. A safety-related shortcoming of the ivermectin-albendazole
co-administration is that it cannot be deployed in areas where also Loa loa is prevalent, since
ivermectin is known to produce severe and possibly fatal adverse reactions such as neurologi-
cal signs, encephalopathy and coma in heavily infected individuals and is thus contraindicated
in endemic West and Central Africa [9]. Alternative treatments with excellent trichuricidal
activity are therefore required. Oxantel pamoate might fill this gap. The drug has been thor-
oughly studied over the past years and in combination with albendazole has shown a high
broad spectrum activity against all STH [24, 71–73] and hence might serve as an excellent
alternative to albendazole-ivermectin.
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